The Impact of Single Nucleotide Polymorphisms of the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Gene on TAFI Antigen Levels in Healthy Children and Pediatric Oncology Patients

Ralf Knoefler; Kathrin Ludwig; Heike Kostka; Eberhard Kuhlisch; Gabriele Siegert; Meinolf Suttorp

doi:10.1055/s-2004-815625

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(6): 575-584
DOI: 10.1055/s-2004-815625

The Impact of Single Nucleotide Polymorphisms of the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Gene on TAFI Antigen Levels in Healthy Children and Pediatric Oncology Patients

Ralf Knoefler¹ , Kathrin Ludwig,¹ , Heike Kostka,² , Eberhard Kuhlisch,³ , Gabriele Siegert² , Meinolf Suttorp¹

¹Department of Pediatric Hematology and Oncology, University Hospital of Technical University, Dresden, Germany
²Department of Clinical Chemistry, University Hospital of Technical University, Dresden, Germany
³Department of Medical Statistics, University Hospital of Technical University, Dresden, Germany

Abstract

ABSTRACT

The thrombin activatable fibrinolysis inhibitor (TAFI) influences the pathways regulating fibrin formation and deposition. The enormous TAFI plasma level variability present in adults may be explained by a combination of two polymorphisms in the TAFI gene (+1542C>G; 505G>A). We aimed to correlate these two polymorphisms with plasma TAFI antigen concentrations in healthy children and pediatric oncology patients with and without venous thrombosis who were supplied with Broviac central venous catheters. Polymorphisms were detected by restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) amplification, whereas TAFI concentration was determined using a commercial enzyme-linked immunosorbent assay (ELISA). Samples from 57 controls and 67 pediatric patients (11 venous thrombotic complications) were studied. TAFI levels in healthy children and patients were not influenced by gender or age. Compared with the 505GG carriers (wild type), 505AA carriers as well as heterozygous 505GA carriers each exhibited significantly higher TAFI antigen concentrations. In contrast, the lowest TAFI levels were detected in homozygous carriers of the +1542GG polymorphism. A combination of the genotype 505AA (homozygous carrier) and +1542CC (wild type) was present in 13 probands and resulted in the highest TAFI levels. Although in oncologic patients the risk of thrombosis was markedly increased by the heterozygous factor V 1691G>A mutation, the two TAFI polymorphisms investigated exerted no thrombogenic influence.

KEYWORDS

TAFI - polymorphism - thrombosis - oncology - children

Full Text

References

REFERENCES

1 Eaton D L, Malloy B E, Tsai S P, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem . 1991; 266 21833-21838
2 Mosnier L O, von dem Borne A P, Meijers J C, Bouma B N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost . 1998; 80 829-835
3 Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem . 1995; 270 14477-14484
4 Boffa M B, Wang W, Bajzar L, Nesheim M E. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem . 1998; 273 2127-2135
5 Wang W, Boffa M B, Bajzar L, Walker J B, Nesheim M E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem . 1998; 273 27176-27181
6 Juhan-Vague I, Morange P E, Aubert H, on behalf of the HIFMECH study group. et al . Plasma thrombin activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol . 2002; 22 867-873
7 Van Tilburg H N, Rosendaal F R, Bertina R M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood . 2000; 95 2855-2859
8 Chetaille P, Alessi M C, Kouassi D, Morange P E, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost . 2000; 83 902-905
9 Juhan-Vague I, Renucci J F, Grimaux M. et al . Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol . 2000; 20 2156-2161
10 Henry M, Aubert H, Morange P E. et al . Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood . 2001; 97 2053-2058
11 Miller S A, Dykes D D, Plesky H F. A simple salting out procedure for extracting DNA from human nucleated cells (letter). Nucleic Acid Res . 1988; 16 1215
12 Kostka H, Kuhlisch E, Schellong S, Siegert S. Polymorphisms in the TAFI gene and the risk of venous thrombosis (in press). Clin Lab . 2003; 49
13 Bertina R M, Koelemann F R, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
14 Poort S R, Rosendaal F R, Rietsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
15 Brouwers G J, Vos H L, Leebeek F W. et al . A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood . 2001; 98 1992-1993
16 Franco R F, Fagundes M G, Meijers J C. et al . Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica . 2001; 86 510-517
17 Tregouet D A, Aubert H, Henry M. et al . Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet . 2001; 109 191-197
18 Schroeder V, Chatterjee T, Mehta H. et al . Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost . 2002; 88 1020-1025
19 Morange P E, Juhan-Vague I, Scarabin P Y, on behalf of the PRIME study group. et al . Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME study. Thromb Haemost . 2003; 89 544-560
20 Morange P E, Aillaud M F, Nicaud V, Henry M, Juhan-Vague I. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers. Thromb Haemost . 2001; 86 1583-1584
21 Siegert G, Kuhlisch E, Schellong S, Kostka H. Mutations in the TAFI gene and the risk for deep vein thrombosis (abstract). Ann Hematol . 2003; 82 (suppl 1) (abstract) S82
22 Kostka H, Schellong S, Kuhlisch E, Siegert S. Mutations in the TAFI gene are not associated with higher risk of venous thrombosis (abstract). J Lab Med . 2002; 26 530
23 Bertina R M. Genetic approach to thrombophilia. Thromb Haemost . 2001; 86 92-103
24 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost . 2001; 86 395-403
25 Nowak-Göttl U, Koch H G, Aschka I. et al . Resistance to activated protein C (APCR) in children with venous and arterial thromboembolism. Br J Haematol . 1996; 92 992-998
26 Schobess R, Junker R, Auberger K, Münchow N, Burdach S, Nowak-Göttl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis-Evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. Eur J Pediatr . 1999; 158 (suppl 3) S105-S108
27 Nowak-Göttl U, Wermes C, Junker R. et al . Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood . 1999; 93 1595-1599
28 Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora K W. Clinical relevance of genetic risk factors for thrombosis in pediatric oncology patients with central venous lines. Eur J Pediatr . 1999; 158 (suppl 3) S143-S146